Roche stock price forecast based on technical charts

Based on technical charts, Roche stock price forecast points towards a bullish breakout above CHF 270, supported by the 50-day moving average turning upward for the first time since January Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. Key Topics Covered: 1. Introduction 2. Research & Methodology 2.1 Data Source 2.1.1 Primary Sources 2.1.2 Secondary Sources 2.2 Research Approach 2.2.1 Top-Down Approach 2.2.2 Bottom-Up Approach 2.3 Forecast Projection Methodology 3. Executive Summary 4. Market Dynamics 4.1 Growth Drivers 4.2 Challenges 5. United States Pharmaceutical Market 5.1 Historical Market Trends 5.2 Market Forecast 6. Market Share Analysis 6.1 By Molecule Type 6.2 Product 6.3 By Type 6.4 By Disease 6.5 By Route of Administration 6.6 By Age Group 6.7 By Distribution Channel 6.8 By States 7. Molecule Type 7.1 Biologics & Biosimilars (Large Molecules) 7.1.1 Market Analysis 7.1.2 Market Size & Forecast 7.2 Conventional Drugs (Small Molecules) 8. Product 8.1 Branded 8.1.1 Market Analysis 8.1.2 Market Size & Forecast 8.2 Generic 9. Type 9.1 Prescription 9.1.1 Market Analysis 9.1.2 Market Size & Forecast 9.2 OTC 9.2.1 Market Analysis 9.2.2 Market Size & Forecast 10. Disease 10.1 Cardiovascular diseases 10.1.1 Market Analysis 10.1.2 Market Size & Forecast 10.2 Cancer 10.3 Diabetes 10.4 Infectious diseases 10.5 Neurological disorders 10.6 Respiratory diseases 10.7 Autoimmune diseases 10.8 Mental health disorders 10.9 Gastrointestinal disorders 10.10 Women's Health Diseases 10.11 Genetic and Rare genetic diseases 10.12 Dermatological conditions 10.13 Obesity 10.14 Renal diseases 10.15 Liver conditions 10.16 Hematological disorders 10.17 Eye conditions 10.18 Infertility conditions 10.19 Endocrine disorders 10.20 Allergies 10.21 Others 11. Route of Administration 11.1 Oral 11.1.1 Market Analysis 11.1.2 Market Size & Forecast 11.2 Topical 11.3 Parenteral 11.4 Inhalations 11.5 Other 12. Age Group 12.1 Children & Adolescents 12.1.1 Market Analysis 12.1.2 Market Size & Forecast 12.2 Adults 12.3 Geriatric 13. Distribution Channel 13.1 Hospital Pharmacy 13.1.1 Market Analysis 13.1.2 Market Size & Forecast 13.2 Retail Pharmacy 13.3 Others 14. Top 10 States 14.1 California 14.1.1 Market Analysis 14.1.2 Market Size & Forecast 14.2 Texas 14.3 New York 14.4 Florida 14.5 Illinois 14.6 Pennsylvania 14.7 Ohio 14.8 Georgia 14.9 Washington 14.10 New Jersey 14.11 Rest of United States 15. Value Chain Analysis 16. Porter's Five Forces Analysis 16.1 Bargaining Power of Buyers 16.2 Bargaining Power of Suppliers 16.3 Degree of Competition 16.4 Threat of New Entrants 16.5 Threat of Substitutes 17. SWOT Analysis 17.1 Strength 17.2 Weakness 17.3 Opportunity 17.4 Threats 18. Pricing Benchmark Analysis 18.1 F. Hoffmann-La Roche Ltd 18.2 Novartis Ag 18.3 Abbvie Inc. 18.4 Johnson & Johnson Services, Inc. 18.5 Merck & Co., Inc. 18.6 Pfizer Inc. 18.7 Bristol-Myers Squibb Company 18.8 Sanofi 18.9 GSK Plc., 18.10 Takeda Pharmaceutical Company Limited 19. Key Players Analysis Roche stock price forecast has been revised upward by JP Morgan, with target CHF 285, assuming rapid adoption of the company’s new breast cancer drug globally.